Capsida Biotherapeutics Presents New Preclinical Evidence Indicating Novel First-in-Class IV-Administered Gene Therapy Effectively Treats Genetic Epilepsy Due to STXBP1 Mutations

/PRNewswire/ -- Capsida Biotherapeutics ("Capsida") today announced new preclinical data supporting the potential of Capsida's gene therapy candidate, CAP-002,...

Related Keywords

,Mingshan Xue ,Capsida Biotherapeutics ,Wu Chen ,Susan Catalano ,Human Genetics At Baylor College Of Medicine ,Department Of Molecular ,Capsida Program For Genetic Epilepsy Due ,Baltimore Convention Center ,Baylor College Of Medicine ,Department Of Neuroscience ,American Society Of Gene Cell Therapy ,Cain Foundation Laboratories ,Associate Professor ,Human Genetics ,Baylor College ,Dan Duncan Neurological Research Institute ,Texas Children ,Therapy Corrects Neurological Phenotypes ,Clinically Relevant Doses ,Mouse Model ,Related Developmental ,Epileptic Encephalopathy ,American Society ,Cell Therapy ,Neurologic Diseasesi Session ,Next Generation Capsids ,Chief Scientific Officer Susan Catalano ,Genetic Epilepsy Due ,